



A Risk Assessment Tool for Predicting Fragility
Fractures and Mortality in the Elderly
Citation for published version (APA):
Tran, T., Bliuc, D., Pham, H. M., van Geel, T., Adachi, J. D., Berger, C., van den Bergh, J., Eisman, J. A.,
Geusens, P., Goltzman, D., Hanley, D. A., Josse, R. G., Kaiser, S. M., Kovacs, C. S., Langsetmo, L.,
Prior, J. C., Nguyen, T., Center, J. R., & CaMos Research Group (2020). A Risk Assessment Tool for
Predicting Fragility Fractures and Mortality in the Elderly. Journal of Bone and Mineral Research, 35(10),
1923-1934. https://doi.org/10.1002/jbmr.4100





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Nov. 2021
ORIGINAL ARTICLE
A Risk Assessment Tool for Predicting Fragility Fractures
and Mortality in the Elderly
Thach Tran,1,2 Dana Bliuc,1,2 Hanh M Pham,1,3 Tineke van Geel,4 Jonathan D Adachi,5 Claudie Berger,6
Joop van den Bergh,7,8,9 John A Eisman,1,2,10 Piet Geusens,9 David Goltzman,11 David A Hanley,12
Robert G Josse,13 Stephanie M Kaiser,14 Christopher S Kovacs,15 Lisa Langsetmo,16 Jerilynn C Prior,17
Tuan V Nguyen,1,2,10,18 and Jacqueline R Center,1,2 and for the CaMos Research Group
1Osteoporosis and Bone Biology, Garvan Institute of Medical Research, Sydney, Australia
2Clinical School, St Vincent’s Hospital, Faculty of Medicine, UNSW Sydney, Sydney, Australia
3Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
4Department of Data and Analytics, Máxima Medical Centre, Veldhoven, The Netherlands
5Department of Medicine, McMaster University, Hamilton, Canada
6Research Institute of the McGill University Health Centre, Montreal, Canada
7Department of InternalMedicine, Subdivision of Rheumatology,Maastricht UniversityMedical Center, Research School Nutrim,Maastricht, TheNetherlands
8Department of Internal Medicine, VieCuri Medical Centre of Noord-Limburg, Venlo, The Netherlands
9Biomedical Research Institute, University Hasselt, Hasselt, Belgium
10School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia
11Department of Medicine, McGill University, Montreal, Canada
12Department of Medicine, University of Calgary, Calgary, Canada
13Department of Medicine, University of Toronto, Toronto, Canada
14Department of Medicine, Dalhousie University, Halifax, Canada
15Faculty of Medicine, Memorial University, St. John’s, Canada
16School of Public Health, University of Minnesota, Twin Cities, Minneapolis, MN, USA
17Department of Medicine and Endocrinology, University of British Columbia, Vancouver, Canada
18School of Biomedical Engineering, University of Technology, Sydney, Australia
ABSTRACT
Existing fracture risk assessment tools are not designed to predict fracture-associated consequences, possibly contributing to the current
undermanagement of fragility fractures worldwide. We aimed to develop a risk assessment tool for predicting the conceptual risk of fragility
fractures and its consequences. The study involved 8965 people aged ≥60 years from the Dubbo Osteoporosis Epidemiology Study and the
Canadian Multicentre Osteoporosis Study. Incident fracture was identified from X-ray reports and questionnaires, and death was ascertained
though contactwith a familymember or obituary review.Weused amultistatemodel to quantify the effects of thepredictors on the transition
risks to an initial and subsequent incident fracture and mortality, accounting for their complex interrelationships, confounding effects, and
death as a competing risk. Therewere 2364 initial fractures, 755 subsequent fractures, and 3300 deaths during amedian follow-up of 13 years
(interquartile range [IQR] 7–15). The predictionmodel included sex, age, bonemineral density, history of falls within 12 previousmonths, prior
fracture after the age of 50 years, cardiovascular diseases, diabetesmellitus, chronic pulmonary diseases, hypertension, and cancer. Themodel
accurately predicted fragility fractures up to 11 years of follow-up andpost-fracturemortality up to 9 years, ranging from7 years after hip frac-
tures to 15 years after non-hip fractures. For example, a 70-year-old woman with a T-score of −1.5 and without other risk factors would have
10% chance of sustaining a fracture and an 8% risk of dying in 5 years. However, after an initial fracture, her risk of sustaining another fracture
or dying doubles to 33%, ranging from 26% after a distal to 42% post hip fracture. A robust statistical technique was used to develop a pre-
dictionmodel for individualization of progression to fracture and its consequences, facilitating informed decisionmaking about risk and thus
treatment for individuals with different risk profiles. © 2020 American Society for Bone and Mineral Research.
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Introduction
Fragility fractures impose a significant public health problemglobally as they are highly prevalent(1,2) and are associated
with significant morbidity and mortality(3–6) and substantial eco-
nomic burden.(7) From the age of 50 years, approximately 16%
and 32% of women in the United States will experience a hip
or clinical vertebral fracture, respectively, compared with a 9%
lifetime risk of developing breast cancer and 3% risk of develop-
ing endometrial cancer.(1,2) Both hospitalization burden and
population facility-related hospital costs for fragility fractures
are significantly greater than those for myocardial infarction,
stroke, and breast cancer in American postmenopausal
women.(7) The 1-year excess mortality after hip, femur, or pelvis
fracture is also higher than the excess mortality for up to 5 years
after the diagnosis of breast cancer in women and prostate can-
cer in men.(4,8) In addition to mortality, survivors after an initial
fracture also have an increased risk of subsequent fracture,(5)
increased dependence, and reduced quality of life.(6) It is thus
critical to identify individualized risk of both fragility fracture
and its related consequences to be able to make meaningful
decisions about appropriate interventions to prevent not only
the first fracture but also the deleterious consequences triggered
by the first fracture.
Several fracture risk assessment tools have been developed to
predict the risk of an initial fragility fracture, assisting clinical deci-
sion making and improving quality of health care.(9–11) Neverthe-
less, no risk assessment tool has been specifically designed to
predict the risk of post-fracture consequences, such as subsequent
fracture or mortality, though the conceptual risk of both fragility
fracture and fracture-related complications is more informative
than the risk of an initial fracture alone. The perceived risk of both
fracture and its consequences is crucial for informed decision mak-
ing and individualized health care planning, potentially contribut-
ing to global efforts to address the undermanagement of fragility
fractures.(12,13)
Several studies have attempted to assess the risk of both fra-
gility fracture and either post-fracture mortality(14) or immobili-
zation(15) among postmenopausal women. However, the
predictors were solely derived from the literature(14) or selected
from separate regression models,(15) failing to account for the
complex interrelationship between these correlated outcome
events and thus possibly resulting in biased estimates.(16) To
develop an assessment tool capable of predicting the risk of spe-
cific fractures and their related outcomes, the study should be of
a large enough size and long enough to observe sufficient post-
fracture consequences. Ideally, it should also be a representative
sample of a whole population. The statistical methods should be
comprehensive and robust to account for the interrelationships
between fracture and its consequences and to objectively select
the most optimal prediction model.
Multistate disease progressionmodels were originally designed
to simultaneously model a series of correlated outcome events
during a stochastic process in a single framework, with robust
accounting for their correlated nature.(16) Importantly, the multi-
state models are also able to take into account the competing of
death and thus allow for unbiased estimates of each correlated
outcomes separately.(17) The multistate model has been shown
to be superior to the traditional Cox proportional models when
examining the risk of correlated time-to-event outcomes.(18)
We thus aimed to develop a risk assessment tool to quantify
the probabilities of both an initial fragility fracture and its related
outcomes of subsequent fracture and mortality using a multi-
state model. The model was then further refined for specific
types of initial fracture, broadly categorized as hip, vertebral,
non-hip non-vertebral proximal, and distal fractures.
Materials and Methods
Study population
The study involved two similar prospective population-based
cohort studies: the Dubbo Osteoporosis Epidemiology Study
(DOES) and the Canadian Multicentre Osteoporosis Study
(CaMos), for which the protocols and procedures have been
described in detail elsewhere.(19,20) Briefly, for the DOES, through
the electoral roll and viamedia campaign, all men andwomen 60
+ years old as of 1989, living in Dubbo city (a regional city of
32,000 predominantly white people in New South Wales,
Australia) were invited to participate in the study. The age and
sex distribution of the Dubbo city population was known to
closely resemble the Australian population.(19) Similarly, the
CaMos is a national population-based prospective cohort study
with an age-, sex-, and region-specific random sampling of the
Canadian population surrounding nine urban centers from coast
to coast. Between 1995 and 1997, community-dwelling partici-
pants were invited to participate in the study if they lived within
a 50-km radius of one of the following nine Canadian cities:
St. John’s, Halifax, Quebec City, Kingston, Toronto, Hamilton, Sas-
katoon, Calgary, and Vancouver. The DOES study involved
approximately 60% of the Dubbo population,(19) whereas the
CaMos represented 40% of the Canadian population in 1995.(20)
The current analysis included 6197 women (2016 from the DOES
and 4181 from the CaMos) and 2768 men (1198 and 1570 from
the DOES and the CaMos, respectively) aged 60 years or older
at study entry (Fig. 1).
Anthropometric data, lifestyle factors, history of falls (ie, self-
reported falls during the previous 12 months), prior fracture
(any fracture after the age of 50 years before recruitment),
comorbidities, and areal bone mineral density (BMD) were col-
lected biennially for the DOES or 5 yearly for the CaMos. BMD
was measured at the femoral neck by dual-energy X-ray absorp-
tiometry. BMD T-scores at the femoral neck collected in the
CaMos and the DOES cohort were derived using the published
reference standards for Canadians(21) and Australians,(22,23)
respectively. Additionally, the physical activity index calculated
as minutes/week in the DOES cohort was dichotomized using
tertiles(24) to match the regular physical activity variable in the
CaMos cohort. Self-reported comorbidities at the time of inter-
view were cardiovascular diseases (CVD; including heart failure,
myocardial infarction, or stroke), cancer (excluding skin cancer),
Paget’s disease of bone, rheumatoid arthritis, osteoarthritis, thy-
roid, liver or kidney disease, hypertension, neuromuscular dis-
eases, diabetes mellitus (DM), venous thromboembolism, and
chronic obstructive pulmonary diseases (COPD).
Fracture assessment
Incident fractures were continuously ascertained from 1989 until
July 2018 for the DOES by review of X-ray reports from all three
radiological services for the entire Dubbo area, or between
1995 and 2013 for the CaMos by annual posted self-reported
questionnaire and verified from medical records or from tele-
phone interview. Fractures in the CaMoswere radiologically con-
firmed in approximately 78% of cases.(25) Only minimal trauma
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fractures involving trauma less than or equivalent to fall from
standing height were included. Potential pathological fractures
(from Paget’s disease or metastatic cancer) or fractures of the
skull, face, finger, and toe were excluded from the analysis. The
first fracture event after recruitment was the initial fracture, while
the next separate fracture event occurring after the first fracture
was the subsequent fracture. Due to low fracture numbers, all
further fracture incidents were not included as separate states.
If an individual had sustained more than one fracture during
one event, the fracture event was classified by the skeletal site
of the more serious fracture. Initial fractures were broadly classi-
fied into hip, clinical vertebral, non-hip non-vertebral proximal
(ie, clavicle, rib, humerus, elbow, pelvis, upper leg), and distal
fractures (forearm, lower leg, knee, ankle, hand, foot).(26)
Mortality ascertainment
Mortality incidence was ascertained through contact with a
member of the participant’s family or a contact person (if the
annual questionnaire was not returned) for the CaMos or obitu-
ary review with verification from the New South Wales Births,
Deaths and Marriages registry for the DOES.
Statistical analysis
The incidence rate for fracture and mortality was estimated for
1000 and 100 person-years of follow-up, respectively, assuming
a Poisson distribution. We used amultistate model(18) to quantify
the effects of predictors on occurrence of initial fracture, subse-
quent fracture and mortality, and the focused information crite-
rion approach(27) to search for the most optimal prediction
model.
We used a progressive multistate model with time as a contin-
uous variable using the exact time of event occurrence to model
the longitudinal course of transition to and after a fragility frac-
ture (Supplemental Fig. S1). The recruitment date and self-
reported date of fractures and death were used to estimate the
time interval from the study entry to the outcome events of
interest (ie, the time on study). Previous studies have shown that
time-on-study analyses making adjustment for age at entry pro-
vided similar results to those using age as the primary time scale
in many scenarios similar to ours.(28,29) The model included four
states: (i) state 1 (individuals alive and free of incident fracture)
for all participants; (ii) state 2 (initial fracture) for those who sus-
tained a fragility fracture during the study follow-up; (iii) state
3 (subsequent fracture) for those who had a second fracture;
and (iv) state 4 (death) for those who died during the follow-up
period. The model provides estimated probabilities that an indi-
vidual with a specific risk profile, characterized by the presence
or absence of one or more predictors from the optimal predic-
tion model, would move from one state to another state
(denoted as qi-j) during a given time. For instance, q1_2 is the
probability of sustaining an initial fracture during a particular
time line (ie, moving from no fracture state [state 1] to fracture
state [state 2]) or q2-4 the probability a person with a fracture
would die (moving from fracture state [state 2] to all-cause death
[state 4]). As a result, the model is able to quantify the individu-
alized risk of both fragility fractures and mortality for an individ-
ual who is fracture free (state 1) or who already has a fracture
(state 2), and the risk of death after a subsequent fracture (state
3). The multistate model was fitted using the maximum likeli-
hood method with the R ‘msm’ package under an assumption
that the intensities are constant or piecewise constant for time-
dependent variants and the time scale variable enters the likeli-
hood through the differences between successive times.(30)
The potential predictors, including baseline demographics
(sex, age, history of falls, prior fracture), lifestyle factors (smoking,
physical activity, alcohol assumption), and specific comorbidities
were systematically examined together to search for the optimal
prediction model. Age was used as a time-variant covariate (ie,
age at baseline for all transitions from state 1, age at an initial
fracture for those from state 2, and age at a subsequent fracture
from state 3) to minimize an immortal bias since participants
who lived longer were more likely to experience a fragility
Fig 1 Flowchart of recruitment and follow-up. Non-hip non-vertebral proximal fractures include clavicle, rib, humerus, elbow, pelvis, and upper leg frac-
ture; non-hip non-vertebral distal fractures include forearm, lower leg, knee, ankle, hand, and foot fracture.
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fracture. Other predictors were considered fixed using their sta-
tus at recruitment under an assumption of little change over
follow-up time intervals.(18,31) Our study did not incorporate
treatment for osteoporosis into the prediction model because
making inferences on the effects of treatment from observa-
tional data is subject to potential biases and confounding
effects.(32) The analysis approach would require using a sub-
group of untreated participants who would have the same
chance of getting treated as those people who were on
treatment,(33) which would impair the representativeness of the
overall study population, making development of a prediction
model not possible. There were no missing data for the out-
comes of interest (ie, initial and subsequent incident fracture,
death), but several potential predictors had missing data (ie,
self-reported comorbidities [1% to 2%] and BMD [10.7%]). We
performed multivariate imputation by chained equations
(MICE) algorithm(34) using the predictive mean matching and
logistic regression method to impute the most plausible values
of missing data for continuous and binary variables, respectively.
Every variable has its own imputation equation. We also carried
out a sensitivity analysis including only participants with avail-
able data for all potential predictors to assess the robustness of
our findings.
The model comparison used the focused information crite-
rion (FIC) approach that was originally designed to search for
the “best” model most suitable for each outcome under con-
sideration, making it particularly robust for simultaneously
modeling multiple correlated outcomes.(27) Thus different
models might be better for different outcomes. The model
selection process started with a “wide”model having the high-
est predictive accuracy as it included all potential predictors
collected for the study regardless of their statistical signifi-
cance.(27) The “narrow” model (ie, the most parsimonious pre-
diction model with the established evidence of good
prediction accuracy) included sex, age, BMD, history of falls,
and prior fracture. The narrow model includes the risk factors
in one of the existing fracture risk assessment tools (ie, the
Garvan fracture risk calculator) that has been shown to be
accurate for fracture prediction.(35,36) The potential predictive
sub-models were then created by adding each potential pre-
dictor to the narrow model.(27,37) We calculated the adjusted
mean residual squared error (MRSE) that quantifies the differ-
ence in predictive accuracy between the sub-model and the
full model and the FIC that quantifies the predictive accuracy
difference adjusted for number of predictors in the sub-
models for each individual sub-model. The optimal prediction
model is ideally the sub-model with the smallest MRSE and
FIC, resulting in a model with fewest predictors and the best
predictive accuracy compared with the full model with all
potential predictors. If the ranking of MRSE is not consistent
with FIC, the optimal model should be selected, taking other
factors such as a compromise between the more complex
model with higher predictive accuracy and the simpler but
less accurate model into account.(38) The MRSE and FIC were
calculated using the R ‘fic’ package.(38)
To maximize the predictive accuracy, we used the weighted
average of all MRSEs, averaging the individual MRSEs for each
specific outcome of interest (initial fracture, subsequent fracture,
and mortality) to search for a single prediction model with the
smallest average MRSE combining all outcomes of interest in
the one model.(38) As the predictive performance was our pri-
mary goal, the predictors of one specific outcome might not be
statistically associated with another outcome after taking into
account the inevitable correlations between these out-
comes.(37,39) Data management and analyses were conducted
using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA), and R
statistical environment (R Foundation, Vienna, Austria; https://
www.rproject.org) on a Windows platform (Microsoft Corp., Red-
mond, WA, USA).
Results
The study involved 8965 individuals aged 60 years or older with
an average age of 70 years who were followed up to a total of
108,005 person-years for incident fractures and mortality
(Fig. 1). Women and men sustained initial and subsequent frac-
tures at similar ages (age at an initial fracture was 78  7.6 years
for women and 78  7.6 years for men, and subsequent fracture
was at 80  7.1 years for women and 81  7.2 years for men)
(Table 1). There were 1351 individuals (18.7% of women and
7.0% of men) found to meet BMD criteria for osteoporosis (T-
score < −2.5) at the study entry. Approximately two-thirds of
the study population had at least one reported disease at the
study entry with the most common comorbidities being hyper-
tension (41.1%), CVD (20.7%), COPD (10.1%), or diabetes mellitus
(9.8%).
Incidence rate of fracture and mortality:
During a median follow-up of 13 years (interquartile range [IQR]
7–15), 1891 women and 473 men sustained an incident initial
fracture, yielding incidence rates of 29.9/1000 person-years
(95% confidence interval [CI] 28.6–31.3) and 16.0/1000 person-
years (14.6–17.5), respectively. Non-hip non-vertebral distal frac-
tures were the most common fracture group in women (10.5
fractures/1000 person-years), while non-hip non-vertebral proxi-
mal fractures (5.3 fractures/1000 person-years) were the most
common initial fracture group in men.
During the follow-up, a third of women with incident fractures
and a quarter of men with incident fractures sustained another
fracture (Table 2). The incidence rate of subsequent fracture
was 66/1000 person-years (95% CI 61.1–71.3) and 50.6/1000
person-years (42.1–60.8), in women andmen, respectively. There
was a total of 3300 deaths during the follow-up (mortality rates
3.2/100 person-years [95% CI 3.0–3.3] in women and 4.3/100
person-years (4.1–4.6) in men). Regardless of specific comorbid-
ities, these elderly women and men who had sustained either
an initial fracture at hip, clinical vertebrae or a proximal site, or
a subsequent fracture had a greater associated mortality risk
than those who remained fracture-free (Supplemental Fig. S2).
Additionally, women with DM and men with COPD or CVD had
the highest mortality rates, irrespective of their fracture status.
The model for predicting fragility fractures and mortality
Our analysis searched for a single prediction model capable of
accurately predicting all correlated outcomes of interest simulta-
neously, accounting for not only their complex interrelationships
and possible confounding effects but death as a competing risk
as well. The optimal prediction model included sex, age, BMD,
history of falls, prior fracture, and comorbidities including CVD,
DM, COPD, hypertension, and cancer (Table 3). This model had
the smallest average RMSE and FIC, indicating its accuracy in
simultaneously predicting the occurrence of an initial fracture,
subsequent fracture, and mortality closest to the full model with
all potential predictors. Sex and age were important predictors
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for both fragility fracture and mortality. By contrast, low BMD,
history of falls, and prior fracture were predominantly related
to fracture risk and comorbidities (CVD, DM, COPD, hypertension,
and cancer) related to mortality risk. After an initial fragility frac-
ture, sex, history of falls, presence of CVD, and COPDwere no lon-
ger independent predictors of a subsequent fracture. Being
female, a history of falls, and presence of CVD or COPD were
associated with about 12%, 7%, 22%, and 16%, respectively,
increased risks for subsequent fracture, though these associa-
tions did not reach statistical significance, probably due to small
number of subsequent fractures. This model was nevertheless
found to be able to predict the risk of subsequent fracture accu-
rately (Fig. 2).
The sensitivity analysis was conducted for 7808 participants
(~87% of the primary analysis population) who had available
data for all potential covariates of interest. Participants in the
sensitivity analysis appeared to be about 1 year older at fractures
and death than those in the primary analysis. The differences in
baseline characteristics between alive and dead participants by
the fracture status in the sensitivity analysis were similar to those
in the primary analysis, although some did not reach statistical
significance, probably due to the smaller study population
(Supplemental Table S1). There was no difference in the inci-
dences of fractures or mortality between the two analyses. Most
importantly, in both analyses, the model with age, BMD T-score,
history of falls, prior fracture, and specific comorbidities (CVD,
hypertension, diabetes mellitus, pulmonary diseases, and can-
cer) had the smallest average RMSE and FIC, suggesting it is
the optimal prediction model.
Fig. 2 assesses to what extent the model accurately predicted
the occurrence of these events of interest by comparing the
observed numbers of individuals in each state of interest (ie,
alive and free of fracture, initial fracture, subsequent fracture,
and death) with their expected events estimated from themodel
during the 15-year period of time. An observed event within 5%
of the expected events is considered acceptably accurate.(30)
Overall, the observed numbers of individuals in each state were
very close to their estimated numbers up to about 11 years of
follow-up for a fracture and 9 years for mortality, indicating the
high accuracy of the model for predicting both fractures and
mortality. The finding that the model somewhat underestimated
the long-term mortality risk beyond 9 years of follow-up war-
ranted further assessment to explore the extent of predictive
accuracy for predicting mortality in different groups of partici-
pants (ie, fracture-free individuals, those with specific types of
fragility initial fracture, or those with any subsequent fracture).
The model was found to be able to predict mortality risk accu-
rately for fracture-free individuals (Supplemental Fig. S3) or those
who had sustained a non-hip fracture (Supplemental Fig. S4) up
to 15 years of follow-up. However, the model only predicted
mortality risk most accurately up to about 7 years after a hip frac-
ture (Supplemental Fig. S4).
Implementation in clinical practice
The model estimates transition risks to fragility fractures and
mortality within a given timeline for an individual with specific
risk profiles. Each specific risk profile is characterized by a partic-
ular value of age and BMD T-score and whether one of the other
predictors (ie, history of falls, prior fracture, and comorbidities,
such as CVD, DM, COPD, hypertension, and cancer) were present.
For simplicity, we illustrate how the model is used to predict the
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70-year-old woman with a low-risk profile (Fig. 3) and with two
arbitrarily selected risk profiles (Supplemental Fig. S5). Fig. 3 illus-
trates how the risks for fragility fractures and mortality are esti-
mated for a 70-year-old woman with BMD T-score of −1.5 and
no other risk factors (ie, no history of falls, no prior fracture, and
no comorbidities [CVD, DM, hypertension, COPD or cancer])
when she is fracture free or already has a fracture. For instance,
a 70-year-old fracture-free woman with a low-risk profile would
have a 9.8% chance of sustaining a fragility fracture. If such a
woman sustains a fracture, the chance of having another fracture
or dying within 5 years are increased up to 33% (16.7% for sub-
sequent fracture and 16.1% for post-initial fracture death).
Although the risk of subsequent fractures did not differ substan-
tially among specific initial fractures, their specific post-fracture
mortality did. Indeed, the 5-year mortality risk after a hip fracture
was 27% compared with 10% after a non-hip non-vertebral distal
fracture. The high competing risk of death associated with hip
fracture would partly explain the similarity in subsequent
fracture risk among specific initial fractures. Finally, a 70-year-
old low-risk woman who sustained a subsequent fracture would
have 27.1% chance of dying within 5 years after this subsequent
fracture. Clearly this mortality risk would vary by fracture type,
but these estimates were beyond the scope of the data.
Supplemental Fig. S5 illustrates different risks of transition to
fractures and mortality for a 70-year-old woman with two differ-
ent risk profiles: (A) BMD T-score=−2.5 and (B) BMD T-score=−2.5
and COPD. As expected, a woman with BMD T-score of −2.5 and
no other risk factors would have greater risk of both initial and
subsequent fractures, but her mortality risk differed little from
the low-risk woman (Supplemental Fig. S5A). Indeed, the proba-
bility of having a fracture in 5 years increased from 10% for the
low-risk woman to 14% for an osteoporotic woman, whereas
the chance she would have another fracture increased from
17% to 22%. By contrast, the presence of low bone mineral den-
sity and COPD would increase both fracture and mortality risk
(Supplemental Fig. S5B). Compared with a low-risk woman, a
Table 2 Numbers of participants in each state during the study follow up by genders and specific types of initial fracture
From initial or transition state Final states until the end of follow up
Women Alive and
fracture-free
Initial fracture Subsequent fracture Death
From fracture-free state (n = 6197) 3051 (49.2%) 1891 (30.5%) NA 1255 (20.3%)
Alive and only initial
fracture
Subsequent fracture Death
From initial fracture state
Specific types of initial fracture:
• Hip (n = 263) 94 (35.7%) 75 (28.5%) 94 (35.7%)
• Vertebrae (n = 443) 154 (34.8%) 173 (39.1%) 116 (26.2%)
• NHNV proximal (n = 522) 236 (45.2%) 176 (33.7%) 110 (21.1%)
• NHNV distal (n = 633) 320 (48.3%) 217 (32.7%) 126 (19.0%)




From subsequent fracture state (n = 641) 369 (57.6%) 272 (42.4%)
Men Alive and
fracture free
Initial fracture Subsequent fracture Death
From fracture-free state (n = 2768) 1307 (47.2%) 473 (17.1%) NA 988 (35.7%)
Alive and only initial
fracture
Subsequent fracture Death
From initial fracture state
Specific types of initial fracture:
• Hip (n = 86) 25 (29.1%) 19 (22.1%) 42 (48.8%)
• Vertebrae (n = 137) 49 (35.8%) 36 (26.2%) 52 (38.0%)
• NHNV proximal (n = 158) 59 (37.3%) 38 (24.1%) 61 (38.6%)
• NHNV distal (n = 92) 45 (48.9%) 21 (22.8%) 26 (28.3%)




From subsequent fracture state (n = 114) 51 (44.7%) 63 (55.3%)
NA = non-applicable; NHNV = non-hip non-vertebrae.
Non-hip non-vertebral proximal fractures include clavicle, rib, humerus, elbow, pelvis, and upper leg fracture; non-hip non-vertebral distal fractures
include forearm, lower leg, knee, ankle, hand, and foot fracture.
Data are frequency (probability) of individuals in each state. For instance, among 6197 women who had entered the study, 3051 (49.2%) remained alive
and fracture-free, 1891 (30.5%) sustained an initial fracture, and 1255 (20.3%) died during the study follow-up. Among 1891 womenwith an initial fracture
(including 263 women with hip, 443 with clinical vertebral, 522 with non-hip non-vertebral proximal, and 633 with distal fractures), 804 (42.5%) had
neither subsequent fracture nor death, 641 (33.9%) developed another fracture, and 446 (23.6%) died. Once sustaining a hip fracture (n = 263),
94 (35.7%) remained alive and had no subsequent fracture, 75 (28.5%) experienced a subsequent fracture, and 94 (35.7%) died. Similarly, among 443
women with the first clinical vertebral fracture, 173 (39.1%) sustained a subsequent fracture and 116 (26.2%) died. Finally, 272 women with a subsequent
fracture (42.4%) died during the follow-up period.
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70-year-old woman with BMD T-score of −2.5 and COPD would
have a 3% absolute higher risk of mortality if fracture free, but
up to 5% and 9% absolute higher mortality risk after an initial
and subsequent fracture, respectively. Her risk of fragility fracture
was also 6% to 7% greater than a similarly aged woman with a
low-risk profile. Interestingly, the transition risks were also modi-
fied by severity of initial fracture. The more severe the initial frac-
ture, the less the risk profiles added to the risk of subsequent
fracture and the more they added to post-fracture mortality risk
(Fig. 3; Supplemental Fig. S5).
Similar patterns were found for a man with different risk pro-
files (Supplemental Fig. S6). A 65-year-old man with a T-score
of −1.5 and without other risk factors would have a 6% chance
of sustaining a fragility fracture and 8% chance of dying in
5 years (Supplemental Fig. S6A). After an initial fracture, his
chance of sustaining another fracture or dying is substantially
increased to 13.5% and 19.1%, respectively. A similarly aged
man with higher risk profile (ie, BMD T-score = −3.0 with prior
fracture, CVD, and COPD but neither history of falls nor other
comorbidities [DM, hypertension, and cancer]) would have
Fig 2 Assessment of model’s accuracy for predicting fragility fractures and mortality.
Table 3 Predictors for Transition Risks to Initial Fractures, Subsequent Fractures and Mortality
Predictors







Sex (women versus men) 1.50 (1.35–1.67) 0.60 (0.55–0.65) 1.12 (0.91–1.37) 0.53 (0.44–0.93) 0.55 (0.41–0.72)
Age (+ 5 years) 1.14 (1.11–1.18) 1.57 (1.53–1.62) 1.12 (1.07–1.19) 1.60 (1.51–1.70) 1.29 (1.19–1.41)
Femoral neck BMD (−1 T-score) 1.44 (1.37–1.50) 1.02 (0.97–1.06) 1.41 (1.30–1.55) 1.06 (0.97–1.15) 1.22 (1.08–1.38)
History of falls within the previous
12 months
1.26 (1.14–1.40) 0.99 (0.89–1.10) 1.07 (0.90–1.26) 1.00 (0.83–1.21) 1.24 (0.98–1.57)
Prior fracture after the age of
50 years before recruitment
1.37 (1.25–1.50) 0.93 (0.83–1.03) 1.19 (1.02–1.40) 0.92 (0.77–1.10) 1.05 (0.51–2.83)
Cardiovascular diseases 1.12 (1.01–1.24) 1.35 (1.23–1.48) 1.22 (0.96–1.55) 1.36 (1.14–1.62) 1.22 (0.96–1.54)
Diabetes mellitus 0.90 (0.77–1.06) 1.61 (1.43–1.81) 1.05 (0.79–1.39) 1.21 (1.03–1.42) 1.15 (0.78–1.68)
Chronic obstructive pulmonary
diseases
1.23 (1.08–1.40) 1.39 (1.23–1.58) 1.16 (0.93–1.43) 1.22 (0.96–1.54) 1.17 (0.87–1.58)
Hypertension 0.98 (0.90–1.06) 1.17 (1.08–1.27) 1.04 (0.90–1.21) 1.20 (0.90–1.59) 1.29 (1.03–1.61)
Cancer 1.14 (0.98–1.32) 1.24 (1.07–1.42) 1.00 (0.79–1.26) 1.00 (0.76–1.31) 1.08 (0.76–1.53)
Data presented as hazard ratios (95% confidence intervals). Boldface indicates statistical significance. Cardiovascular diseases include myocardial infarc-
tion, heart failure, or stroke.
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higher chances of sustaining fragility fractures or dying
(Supplemental Fig. S6B).
Discussion
Individualization of health care is crucial to allow tailoring of pre-
vention and treatment in modern medicine. To our knowledge,
this is the first risk assessment tool developed to predict the
occurrence of not only an initial fracture but also of post-fracture
outcomes, sufficiently accounting for their complex interrela-
tionships. Of clinical importance also is the model’s ability to pre-
dict the risk of post-fracture consequences for a patient with a
particular risk profile who already has a fragility fracture. The
optimal model both in terms of accuracy for prediction and for
clinical applicability included sex, age, BMD T-score, history of
falls, prior fracture, and comorbidities, namely CVD, DM, COPD,
hypertension, and cancer. The model accurately predicted the
occurrence of a fragility fracture and mortality, including the
mortality up to 7 years post-hip fracture and 15 years after an ini-
tial non-hip fracture.
Prediction models are able to objectively incorporate data
from multiple risk factors to estimate reproducible risk, making
them superior to clinical judgment.(40) Despite many attempts
to predict both fracture and its related outcomes, to date none
has been comprehensive and able to account for the complex
interrelationships between these correlated outcomes.(14,15)
Failing to account for the correlated nature of fracture and its
consequences would provide a biased estimation of risk.(18) By
contrast, the multistate model used to develop our prediction
model was specifically designed to quantify the effects of predic-
tors related to progression of an illness to a series of correlated
states, accounting for not only the interrelationships between
these correlated outcomes but confounding effects and compet-
ing risk as well.(18) Death was examined together with other out-
comes in a single regression framework, making it capable of
accounting for the competing risk of other correlated outcomes.
A direct head-to-head comparison between the multistate
model and separate Cox regression models has indicated the
superiority of the multistate model as the former but not the lat-
ter was able to yield new insights into breast cancer progression
and associated pathways to cause-specific mortality.(41) The mul-
tistate model was also able to show the pathways of associations
across the intermediate events between primary breast cancer
and mortality, which are not directly visible with separate Cox
regression models.(41) In addition to sex and age as important
predictors for both fracture and mortality, BMD T-score, history
of falls, and prior fracture were mainly focusing on prediction
of the risk of initial and subsequent fractures and comorbidities
for prediction of mortality, including post-fracture mortality.
We found the prediction model developed in this study could
accurately predict a fragility fracture and its related outcomes for
women and men in the population aged 60+ years. A combina-
tion of sex, age, BMD, prior fracture, and history of falls has been
Fig 3 Predicted 5-year transition risks to fragility fractures andmortality for a 70-year-old womanwith a low-risk profile (femoral neck BMD T-score =−1.5,
no history of falls, no prior fracture, and no comorbidities). Shaded boxes indicate the timing when the estimated risks of future fractures or mortality are
made. For instance, a 70-year-old fracture-free woman with a low-risk profile would have a 9.8% chance of sustaining a fragility fracture and 7.6% chance
of dying in 5 years. After the initial fracture, her chance of having another fracture or dying within 5 years post initial fracture would increase to 16.7% and
16.1%, respectively. Finally, the same woman’s risk of dying within 5 years after the subsequent fracture would increase to 27.1%. Non-hip non-vertebral
proximal fractures include clavicle, rib, humerus, elbow, pelvis, and upper leg fracture; non-hip non-vertebral distal fractures include forearm, lower leg,
knee, ankle, hand, and foot fracture.
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found to be able to accurately predict the occurrence of a fragil-
ity fracture(35) and hip fracture,(42) even in many external
cohorts,(9–11) including the CaMos cohort.(36) Our model also sug-
gests that sex, age, and several baseline comorbidities are able to
predict mortality risk not only among fracture-free individuals
but also after an initial or subsequent fracture. Cardiovascular
diseases, COPD, DM, cancer, and hypertension have been long
considered to be the leading causes of death in high-income
countries(43) and independent predictors for mortality after hip
fracture.(44) The prediction model was robust in predicting mor-
tality risk accurately up to 15 years after a non-hip fracture and
7 years post-hip fracture. Regardless of its underestimation of
the long-term mortality risk beyond 7 years post-hip fracture,
the model remains clinically useful because a majority of deaths
occur within 1 year post-hip fracture and certainly by 5 years.(3)
Our findings have important implications for clinical practice.
Unlike the existing fracture risk assessment tools,(9–11) our pre-
diction model is able to predict the conceptual risk of a fragility
fracture and its related consequences, which should make
informed decision making about the risk and potential value of
treatment more convincing than just the estimated risk of an ini-
tial fracture alone. Importantly, the model is also able to predict
the risk of subsequent fracture and mortality for a patient who
already sustained a fragility fracture, making it possible to iden-
tify a fracture patient at particularly high risk in the fracture liai-
son service settings. Lack of information about the risk of
fracture-related consequences may contribute to the current
undermanagement of fragility fractures worldwide.(12,13) This
prediction model with its capacity to provide an individualized
estimate of risk of a fragility fracture and its consequences is
expected to assist both doctors and patients to reach an
informed clinical decision, ultimately improving appropriate
and timely management of a fragility fracture and reducing its
burden among older individuals. This is a critical step to increase
treatment uptake and adherence for those who need it as the
current worldwide undermanagement of fragility fractures is at
least partly related to the fact that neither patients nor primary
care practitioners are sufficiently informed about fragility frac-
ture and its consequences.(45) Indeed, primary care practitioners
usually consider osteoporosis far less important than other
chronic diseases.(46)
No studies to date have examined whether the prospective
use of a fracture risk assessment tool is associated with improved
treatment uptake or adherence. However, prospective incorpo-
ration of a performance algorithm in clinical practice substan-
tially increased the appropriate use of a vertebral fracture
assessment (VFA) on lateral spine images,(47) which in turn signif-
icantly increased subsequent prescription of fracture prevention
medication.(48) Compared with VFA-negative (ie, vertebral frac-
tures were definitely not present), the VFA-positive (ie, vertebral
fracture definitely present) and uncertain (ie, possible vertebral
fractures) were associated with about threefold (odds ratio
[OR] = 2.77; 95% CI 2.40–3.19) and 1.5-fold (OR = 1.43; 95% CI
1.07–1.92) increased odds of dispensing of subsequent fracture
prevention medication, respectively.(48) The impact of VFA on
subsequent use of fracture prevention medication became even
more obvious for individuals with low to moderate estimated
risk of fracture (10% to 20%) or without osteoporosis who other-
wise might not be considered eligible for osteoporosis
treatment.(48)
The results of the current study should be viewed in the con-
text of its strengths and limitations. Its strengths include a large
and homogenous study population and the rigorous analysis
approach. Our study population included approximately 9000
participants from two very similar population-based prospective
cohort studies in which the fracture risk assessment tool had
been developed(42) and externally validated,(36) making the
study population statistically homogenous for the analyses. Our
large study population with a median of 13-year follow-up was
robust to determine the long-term consequences after specific
types of fracture. This model, to our knowledge, is the first pre-
dictionmodel able to quantify the risk of specific types of fragility
fracture and their related long-term consequences, accounting
for the complex intercorrelations that none of the existing frac-
ture assessment tools have accommodated to date. Importantly,
the multistate model is well recognized as a rigorous statistical
method to develop a prediction model for the correlated
ordered outcome events.(18)
Despite these strengths and regardless of large sample size
with long follow-up, our study was not powered to examine
the individual type of non-hip non-vertebral fractures. We thus
grouped them as proximal and distal fractures.(26) Secondly, all
covariates but age were considered fixed under an assumption
that their status at fracture time was not substantially different
from their recruitment status. That is a common practice used
when applying multistate models,(18,31) and clinicians might find
the prediction model with predictors reported when an individ-
ual has not experienced any outcome event more reasonable
and far easier to be implemented in daily practice. Nevertheless,
this assumption might not always be met for several comorbid-
ities, possibly impacting the predictive accuracy for post-fracture
mortality. Finally, the study population was predominantly white
(~97%), so the findings may not be generalizable to other
ethnicities.
Our project did not aim to validate the model’s predictive per-
formance against the existing fracture risk assessment tools.
Instead, we plan to conduct an external validation to verify the
robustness and generalization of the prediction model in other
well-established cohorts. If the model is shown to be acceptably
accurate, a web-based calculator will be developed to assist
users to estimate the probabilities for an incident fragility frac-
ture, subsequent fracture, and mortality for an individual with
different risk profiles. Further studies are needed, if possible, to
examine whether time-dependent predictors, including comor-
bidity status at the time of the intermediate outcome events,
would improve the model’s predictive performance.
In conclusion, we used a novel and robust statistical technique
to develop a risk assessment tool capable of predicting the
occurrence of fragility fracture and its consequences, sufficiently
accounting for not only the complex interrelationships between
these outcomes but also possible confounding effects. The
model can inform decision-making about risk beyond the frac-
ture itself and thus aid in individualized treatment decisions.
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